A Study for GSK3862995B in Healthy Participants and Participants With Chronic Obstructive Pulmonary Disease - Trial NCT06154837
Access comprehensive clinical trial information for NCT06154837 through Pure Global AI's free database. This Phase 1 trial is sponsored by GlaxoSmithKline and is currently Not yet recruiting. The study focuses on Pulmonary Disease, Chronic Obstructive. Target enrollment is 130 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
GlaxoSmithKline
Timeline & Enrollment
Phase 1
Nov 27, 2023
Mar 13, 2026
Primary Outcome
Part A: Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs),Part B: Number of Participants with AEs and SAEs,Part A: Number of Participants with Clinically significant changes in laboratory values,Part A: Number of Participants with Clinically Significant Change in vital signs,Part A: Number of Participants with Clinically Significant Change in 12-lead Electrocardiogram (ECG) Parameters,Part B: Number of Participants with Clinically significant changes in laboratory values. (haematology, chemistry and urinalysis),Part B: Number of Participants with Clinically Significant Change in vital signs,Part B: Number of Participants with Clinically Significant Change in 12-lead Electrocardiogram (ECG) Parameters
Summary
The primary objective of the study is to investigate the safety and tolerability of ascending
 doses of GSK3862995B following single dose in healthy participants and repeat doses in
 participants with Chronic obstructive pulmonary disease (COPD).
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06154837
Non-Device Trial